ArticleInflammatory bowel diseases2022
Health Care Costs and Resource Utilization Among Patients With Crohn's Disease With and Without Perianal Fistula.
Article in Inflammatory bowel diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Treatment of complex perianal fistulas with fistula laser closure : Application of the IDEAL 2A framework.Wiener klinische Wochenschrift · 2026Article
- When nothing else matters: proctectomy for complex perianal Crohn's disease-indications, timing, techniques, and outcomes.Techniques in coloproctology · 2026Review
- Scrotal abscesses in perianal Crohn's disease: a retrospective cohort study of clinical presentation, management, and outcomes.Techniques in coloproctology · 2026Article
- Bayesian prior elicitation on the efficacy of medical therapies in perianal fistulizing Crohn's disease.Journal of Crohn's & colitis · 2026Article
- Subcutaneous infliximab in the treatment of patients with perianal fistulizing Crohn's disease: current evidence and emerging roles.Therapeutic advances in gastroenterology · 2026Review
- Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real-Life Retrospective Multicentre Cohort Study.Alimentary pharmacology & therapeutics · 2025Article
- Impact of SCN10A Polymorphism on Abdominal Pain Perception and Visceral Hypoalgesia in Crohn's Disease and Ulcerative Colitis.Clinical and translational gastroenterology · 2024Article
- Fistulizing Perianal Disease as a First Manifestation of Crohn's Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Patient and Caregiver Perspectives on Their Experiences With Crohn's Perianal Fistulas.Crohn's & colitis 360 · 2024Article
- Perianal Fistulas Are Associated with Persistently Higher Direct Health Care Costs in Crohn's Disease: A Population-Based Study.Digestive diseases and sciences · 2023Article
- Multi-national observational study to assess quality of life and treatment preferences in patients with Crohn's perianal fistulas.World journal of gastrointestinal surgery · 2023Article
- Abdominal Pain in Inflammatory Bowel Disease: An Evidence-Based, Multidisciplinary Review.Crohn's & colitis 360 · 2023Article
- Malignancy rates in Crohn's disease patients with perianal fistula: A German retrospective cohort study.United European gastroenterology journal · 2023Article
- Economic burden related to fistulas or strictures among commercially insured patients with Crohn's disease in the United States.Journal of managed care & specialty pharmacy · 2023Article
- Hyperbaric oxygen therapy: More hope than hype for future treatment of perianal fistulizing Crohn's disease?United European gastroenterology journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPerianal fistula (PAF), a complication of Crohn's disease (CD), is associated with substantial economic costs and poor prognosis. We determined prevalence of PAF CD in the United States and compared costs and health care resource utilization (HRU) of PAF CD patients with matched non-PAF CD patients.
methodsThis was a retrospective cohort study of claims data from the IBM MarketScan Commercial Database from October 1, 2015, to September 30, 2018. Eligible patients were aged 18 to 89 years with ≥2 CD diagnoses. Patients with PAF CD had ≥1 PAF diagnosis or procedure code and were matched with non-PAF CD patients. Cumulative prevalence of PAF CD in the US population was calculated across total patients in MarketScan. All-cause and gastrointestinal (GI)-related costs and HRU were compared between groups using a generalized linear model (GLM).
resultsCumulative 3-year prevalence of PAF was 7.70% of patients with CD (N = 81,862) and 0.01% of the US population. Among PAF CD (n = 1218) and matched non-PAF CD (n = 4095) patients, most all-cause costs and HRU were GI-related. Mean total all-cause and GI-related health care costs per patient and per year for PAF CD were $85,233 and $71,612, respectively, vs $40,526 and $29,458 for non-PAF CD (P < .0001). Among PAF CD vs non-PAF CD patients, GLM-adjusted proportions of patients with GI-related inpatient, outpatient, or pharmacy visits, mean GI-related inpatient length of stay, and mean GI-related surgeries were higher (P < .0001 for all comparisons).
conclusionsCosts and HRU are significantly higher for patients with PAF CD vs non-PAF CD patients, highlighting the economic burden of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.